Oramed Pharmaceuticals annual debt-to-equity ratio
2018
2019
2020
2022
2023
2024
2025
Oramed Pharmaceuticals Debt-to-Equity Ratio Growth & History (ORMP)
Oramed Pharmaceuticals's debt-to-equity ratio was 0.00 for fiscal 2025.
View full Oramed Pharmaceuticals company overviewOramed Pharmaceuticals annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.00 | 0.00 | +62.40% |
| 2024 | 2024-12-31 | 0.00 | −0.31 | −99.19% |
| 2023 | 2023-12-31 | 0.32 | 0.31 | +5105.42% |
| 2022 | 2022-12-31 | 0.01 | — | — |
| 2020 | 2020-08-31 | 0.00 | −0.64 | −99.85% |
| 2019 | 2019-08-31 | 0.64 | 0.19 | +43.32% |
| 2018 | 2018-08-31 | 0.44 | — | — |
Oramed Pharmaceuticals quarterly debt-to-equity ratio
Q4.18
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q1.22
Q3.22
Q3.22
Q4.22
Q1.23
Q2.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.00 | −0.00 | −60.88% |
| Q1 2026 | 2026-03-31 | 0.00 | 0.00 | +49.41% |
| Q4 2025 | 2025-12-31 | 0.00 | 0.00 | +62.40% |
| Q3 2025 | 2025-09-30 | 0.00 | 0.00 | +54.27% |
| Q2 2025 | 2025-06-30 | 0.01 | 0.00 | +115.02% |
| Q1 2025 | 2025-03-31 | 0.00 | −0.19 | −98.91% |
| Q4 2024 | 2024-12-31 | 0.00 | −0.31 | −99.19% |
| Q3 2024 | 2024-09-30 | 0.00 | — | — |
| Q2 2024 | 2024-06-30 | 0.00 | −0.00 | −42.55% |
| Q1 2024 | 2024-03-31 | 0.20 | 0.19 | +3559.85% |
| Q4 2023 | 2023-12-31 | 0.32 | 0.31 | +5105.42% |
| Q2 2023 | 2023-06-30 | 0.00 | −0.05 | −91.14% |
| Q1 2023 | 2023-03-31 | 0.01 | — | — |
| Q4 2022 | 2022-12-31 | 0.01 | — | — |
| Q3 2022 · Sep 30 | 2022-09-30 | 0.04 | — | — |
| Q3 2022 · Jun 30 | 2022-06-30 | 0.05 | — | — |
| Q1 2022 · Nov 30 | 2021-11-30 | 0.07 | 0.05 | +216.27% |
| Q3 2021 | 2021-05-31 | 0.01 | 0.01 | +215.10% |
| Q2 2021 | 2021-02-28 | 0.01 | 0.01 | +99.86% |
| Q1 2021 | 2020-11-30 | 0.02 | 0.02 | +267.25% |
| Q4 2020 | 2020-08-31 | 0.00 | −0.64 | −99.85% |
| Q3 2020 | 2020-05-31 | 0.00 | — | — |
| Q2 2020 | 2020-02-29 | 0.01 | — | — |
| Q1 2020 | 2019-11-30 | 0.01 | — | — |
| Q4 2019 | 2019-08-31 | 0.64 | 0.19 | +43.32% |
| Q4 2018 | 2018-08-31 | 0.44 | — | — |
Oramed Pharmaceuticals debt-to-equity ratio trends
Between the periods ended 2018-08-31 and 2025-12-31, Oramed Pharmaceuticals's debt-to-equity ratio decreased from 0.44 to 0.00, a change of −0.44. The latest reported quarter, Q2 2026, shows 0.00.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Oramed Pharmaceuticals source filings ↗